These probiotics have the potential to reduce side effects from primary drug treatments and improve the quality of life for patients.

Further research is advocated to explore the relationships between nasal and oral microbiota and PD, which could reveal new therapeutic targets.

Gut health is crucial for overall wellness, as poor sleep and unhealthy lifestyle choices can negatively impact the gut microbiome, leading to a cycle of fatigue and health issues.

Symptoms of IBD, such as diarrhea and abdominal pain, affect millions worldwide, highlighting the need for effective management strategies.

To maintain a healthy gut, individuals should focus on a diet rich in fiber from fruits, vegetables, and whole grains, while minimizing sugar and fat intake.

Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by the degeneration of dopaminergic neurons, leading to both motor symptoms like bradykinesia and rigidity, and non-motor symptoms such as depression and cognitive impairment.

Approximately 85% of PD cases are sporadic, influenced by a combination of genetic, environmental, and non-genetic risk factors.

Standard treatment for Parkinson's includes levodopa, which increases dopamine levels but often has limited effectiveness due to side effects and poor brain absorption.

Recent research has identified six probiotic strains that do not interfere with levodopa and can produce neurotransmitters like GABA and serotonin, which are often reduced in Parkinson's patients.

Inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn's disease, is linked to dysbiosis in the gut microbiome and presents significant health challenges.

An unhealthy gut microbiome can manifest through various health issues, including digestive problems, fatigue, and skin irritations.

Alzheimer's disease (AD) is another major health concern, affecting over 50 million people globally, with its prevalence increasing significantly with age.